Literature DB >> 29671012

[Cystinosis : Diagnosis, cystine-depleting therapy, and transition].

Jessica Kaufeld1, Lutz T Weber2, Christine Kurschat3, Sima Canaan-Kuehl4, Eva Brand5, Jun Oh6, Lars Pape7.   

Abstract

This article presents a case of cystinosis in a young man. Diagnosis of the disease and the problem of transition to adult care are described. Cystinosis is a rare lysosomal storage disease with first manifestation in early childhood presenting as renal Fanconi syndrome. Without treatment, the disease leads to severe health impairment. Due to the rarity of the disease, a correct diagnosis is often delayed. Without treatment, cystinosis often leads to end-stage renal failure, blindness, hypothyroidism, diabetes mellitus, and rickets. Cystine-depleting therapy with cysteamine significantly improves mortality and quality of life.

Entities:  

Keywords:  Cornea; Cysteamine; Fanconi syndrome; Kidney transplantation; Lysosomal storage diseases

Mesh:

Substances:

Year:  2018        PMID: 29671012     DOI: 10.1007/s00108-018-0416-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.

Authors:  Thurid Ahlenstiel-Grunow; Nele K Kanzelmeyer; Kerstin Froede; Martin Kreuzer; Jens Drube; Christian Lerch; Lars Pape
Journal:  Pediatr Nephrol       Date:  2016-06-27       Impact factor: 3.714

2.  Nephropathic cystinosis--a gap between developing and developed nations.

Authors:  Aurelia Bertholet-Thomas; Justine Bacchetta; Velibor Tasic; Pierre Cochat
Journal:  N Engl J Med       Date:  2014-04-03       Impact factor: 91.245

3.  Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.

Authors:  Elena N Levtchenko; Carin M van Dael; Addy C de Graaf-Hess; Martijn J G Wilmer; Lambertus P van den Heuvel; Leo A Monnens; Henk J Blom
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

4.  Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter.

Authors:  V Kalatzis; S Cherqui; C Antignac; B Gasnier
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

5.  Cysteamine therapy: a treatment for cystinosis, not a cure.

Authors:  Stephanie Cherqui
Journal:  Kidney Int       Date:  2012-01       Impact factor: 10.612

6.  Neurobehavioral consequences of a genetic metabolic disorder: visual processing deficits in infantile nephropathic cystinosis.

Authors:  A O Ballantyne; D A Trauner
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2000-10

7.  Improved renal function in children with cystinosis treated with cysteamine.

Authors:  T C Markello; I M Bernardini; W A Gahl
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

8.  Nephropathic cystinosis: an international consensus document.

Authors:  Francesco Emma; Galina Nesterova; Craig Langman; Antoine Labbé; Stephanie Cherqui; Paul Goodyer; Mirian C Janssen; Marcella Greco; Rezan Topaloglu; Ewa Elenberg; Ranjan Dohil; Doris Trauner; Corinne Antignac; Pierre Cochat; Frederick Kaskel; Aude Servais; Elke Wühl; Patrick Niaudet; William Van't Hoff; William Gahl; Elena Levtchenko
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

9.  Effect of age at treatment on cognitive performance in patients with cystinosis.

Authors:  Lisa Viltz; Doris A Trauner
Journal:  J Pediatr       Date:  2013-02-22       Impact factor: 4.406

10.  Neurocognitive functioning in school-aged cystinosis patients.

Authors:  M T P Besouw; G M Hulstijn-Dirkmaat; R E A van der Rijken; E A M Cornelissen; C M van Dael; J Vande Walle; M R Lilien; E N Levtchenko
Journal:  J Inherit Metab Dis       Date:  2010-09-03       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.